Market closedNon-fractional
Roivant Sciences/ROIV
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Roivant Sciences
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Ticker
ROIV
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
London, United Kingdom
Employees
908
Website
roivant.com
Roivant Sciences Metrics
BasicAdvanced
$7.9B
Market cap
2.05
P/E ratio
$5.23
EPS
1.25
Beta
-
Dividend rate
Price and volume
Market cap
$7.9B
Beta
1.25
Financial strength
Current ratio
25.236
Quick ratio
24.811
Long term debt to equity
7.41
Total debt to equity
7.75
Interest coverage (TTM)
-31.05%
Management effectiveness
Return on assets (TTM)
-14.04%
Return on equity (TTM)
105.04%
Valuation
Price to earnings (TTM)
2.054
Price to revenue (TTM)
67.408
Price to book
1.45
Price to tangible book (TTM)
1.49
Price to free cash flow (TTM)
-10.973
Growth
Revenue change (TTM)
103.65%
Earnings per share change (TTM)
-468.50%
3-year revenue growth (CAGR)
73.74%
3-year earnings per share growth (CAGR)
59.69%
What the Analysts think about Roivant Sciences
Analyst Ratings
Majority rating from 11 analysts.
Roivant Sciences Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q4 24
QoQ growth
Revenue
$29M
-22.10%
Net income
-$151M
-102.97%
Profit margin
-522.83%
-103.81%
Roivant Sciences Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q1 24
Q2 24
Q3 24
Q4 24
Q1 25
Actual
-$0.38
-$0.40
$6.03
-$0.19
-
Expected
-$0.30
-$0.31
-$0.32
-$0.30
-$0.29
Surprise
27.69%
29.63%
-1,984.38%
-37.36%
-
Roivant Sciences News
AllArticlesVideos
The 'Undercovered' Dozen From June 1-6
Seeking Alpha·2 months ago
Roivant Sciences: Executing On Huge Buyback Program With More To Come
Seeking Alpha·2 months ago
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Roivant Sciences stock?
Roivant Sciences (ROIV) has a market cap of $7.9B as of July 27, 2024.
What is the P/E ratio for Roivant Sciences stock?
The price to earnings (P/E) ratio for Roivant Sciences (ROIV) stock is 2.05 as of July 27, 2024.
Does Roivant Sciences stock pay dividends?
No, Roivant Sciences (ROIV) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Roivant Sciences dividend payment date?
Roivant Sciences (ROIV) stock does not pay dividends to its shareholders.
What is the beta indicator for Roivant Sciences?
Roivant Sciences (ROIV) has a beta rating of 1.25. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Roivant Sciences stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.